Skip to main content

Table 2 Modified LDLs, HDL composition and Lp-PLA2 activity in patients with type 2 diabetes and control subjects

From: Impact of the LDL subfraction phenotype on Lp-PLA2 distribution, LDL modification and HDL composition in type 2 diabetes

  Type 2 diabetes phenotype A (n = 77) Type 2 diabetes phenotype B (n = 45) Control group ANOVA
(n = 54) p-value
Modified LDL
Oxidized LDL (U/L) 61.4 ± 20.0 78.6 ± 26.7 a 51.2 ± 19.3 a,b 0.005
Glycated LDL (mg/dL) 2.17 ± 0.94 2.77 ± 1.41 a 1.85 ± 0.73 a,b 0.030
LDL(−) (%) 7.6 ± 3.5 7.7 ± 3.1 6.1 ± 2.0 a,b 0.017
HDL composition
Cholesterol (%)1 17.1 ± 2.3 15.6 ± 3.0 a 17.3 ± 2.3 b 0.204
Trigycerides (%) 4.3 ± 1.7 6.7 ± 1.9 a 3.1 ± 1.0 a,b <0.001
Phospholipids (%) 33.5 ± 4.3 31.3 ± 3.3 a 32.8 ± 3.7 0.076
apoA-I (%) 31.9 ± 5.8 32.8 ± 6.3 34.3 ± 5.7 a,b 0.193
apoA-II (%) 13.2 ± 3.4 13.6 ± 2.6 12.5 ± 2.9 a,b 0.265
NEFA(mol/mol apoA-I) 1.1 ± 0.6 1.0 ± 0.6 1.0 ± 0.9 0.907
Ratio lipid/protein 1.20 ± 0.28 1.19 ± 0.27 1.16 ± 0.27 a,b 0.539
Ratio A-I/A-II 2.61 ± 0.92 2.54 ± 0.81 2.98 ± 1.12 a,b 0.112
Ratio chol/trigl 4.65 ± 2.19 2.57 ± 0.91 6.32 ± 2.68 a,b <0.001
PON1 activity 78.5 ± 25.5 82.6 ± 25.5 82.5 ± 23.1 0.152
(μmol/min/mL)
Lp-PLA2 activity(μmol/min/mL)
Total Lp-PLA2 20.1 ± 6.6 23.0 ± 7.2 a 19.1 ± 6.2 b 0.627
HDL-Lp-PLA2 6.8 ± 2.7 7.1 ± 3.5 6.2 ± 2.6 0.995
apoB-associated-Lp-PLA2 13.3 ± 4.8 15.9 ± 4.6 a 12.9 ± 3.3 b 0.539
% HDL-Lp-PLA2 33.9 ± 10.5 30.9 ± 11.4 a 32.4 ± 10.6 0.510
% apoB-associated-Lp-PLA2 66.1 ± 19.4 69.1 ± 21.2 a 67.6 ± 19.8 0.510
  1. a, P < 0.05 vs phenotype A patients; b, P < 0.05 vs phenotype B patients.
  2. 1 Composition is expressed as the percentage of the mass of cholesterol, triglycerides, phospholipids, apoA-I and apoA-II.